---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000080"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-08-05T20:06:08+00:00"
generated_at: "2026-08-05T20:09:27.355733+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q2 revenue up 66% to $234M, net loss $180M on $191M impairment; restructuring cuts 93 jobs

## Summary
- Q2 total revenues $234.3M (+66% YoY); adjusted net income $30.9M (+134% YoY); GAAP net loss $180.2M due to $191.3M non-cash impairment on NARCAN asset group.
- Restructuring plan: cut ~93 employees, close Gaithersburg wet labs; expected annualized savings ~$40M, charges $10M-$11.5M in H2 2026.
- Simon Lowry (CMO, Head of R&D) departing Aug 19; Stephanie Duatschek named EVP, Chief Growth Officer.
- Naloxone revenue down 22% to $52.4M; Smallpox MCM up 150% to $101.6M; Other Products (BAT) up to $54.1M.

## SEC filing metadata
- accession: 0001367644-26-000080
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-08-05T20:06:08+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/0001367644-26-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000080
- JSON: https://secwatch.observer/filing/0001367644-26-000080.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.